Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
A single shot of HPV vaccine may be enough to fight cervical cancer, study finds - 24 injured in suburban Philadelphia nursing home explosion file negligence lawsuit
- 3Tech giants accused of not complying with Australian social media ban
- 4Lula’s former human rights minister formally accused of sexual misconduct
- 5Gauging the Upsides and downsides of Visas: A Complete Aide
- Allow Innovative Progressions To have a Massive Effect
- The Extraordinary Excursion of Dental Embed Innovation
- NASA to bring astronauts home from space station early due to a medical issue
- Vote in favor of your favored spot to peruse
- Arctic sea ice hits lowest winter level as unprecedented heat hits smashes records all over Earth
- What's the Fate of 5G Innovation?
- Over 250,000 cases of shredded cheese recalled over possible metal fragments
- Vote in favor of your Number one Sort of Cap
- Australia PM tries to reassure public as panic buying sees fuel demand surge 400% in some regions
